ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm

As doctors weigh various immunotherapy strategies for the treatment of early-stage non-small cell lung cancer, Merck & Co. has now unveiled new data that it hopes can establish Keytruda, used both before and after surgery, as a new standard of care.